Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6797
-0.1103-13.96%
Post-market: 0.69200.0123+1.81%19:51 EST
Volume:9.20M
Turnover:6.49M
Market Cap:147.16M
PE:-0.94
High:0.8100
Open:0.7916
Low:0.6500
Close:0.7900
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:3.50
T/O Rate:4.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7209
EPS(LYR):-1.3101
ROE:-96.44%
ROA:-49.48%
PB:1.78
PE(LYR):-0.52

Loading ...

Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan

TIPRANKS
·
Jan 31

Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise

Simply Wall St.
·
Jan 23

Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating

TIPRANKS
·
Jan 10

Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating

TIPRANKS
·
Jan 10

BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities

Reuters
·
Jan 09

Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027

Reuters
·
Jan 09

Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-201 in 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-401 in H2 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Inc - Raised $60 Mln in 4Q25 to Support Runway Through Mid-2027

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics - Expects to Report One-Year Cohort 1 Data & Early Cohort 2 Data From Ridge-1 Study of Tn-401 for Pkp2-Associated Arvc in H1 2026

THOMSON REUTERS
·
Jan 09

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

GlobeNewswire
·
Jan 09

Tenaya Therapeutics Director David Goeddel Resigns Effective January 2026

Reuters
·
Jan 03

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 19, 2025

Tenaya Therapeutics (TNYA) Is Down 39.7% After FDA Lifts TN-201 Hold and Trial Updates - What's Changed

Simply Wall St.
·
Dec 13, 2025

Tenaya Stock Plunges After $60 Million Equity Offering

Benzinga_recent_news
·
Dec 13, 2025

Tenaya Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $3 From $5

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 12, 2025

Tenaya Therapeutics Announces Pricing of Public Offering

THOMSON REUTERS
·
Dec 12, 2025

BUZZ-Tenaya Therapeutics slides after launching stock offering

Reuters
·
Dec 12, 2025

BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition

Reuters
·
Dec 12, 2025